Your session is about to expire
← Back to Search
AGEN1777 + PD-1 Inhibitor for Cancer
Study Summary
This trial is testing a new drug, AGEN1777, to see if it is safe and effective when used alone or with a different drug, a PD-1 inhibitor, to treat advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.My cancer is advanced, and standard treatments have failed or are not suitable.I am expected to live at least 3 more months and can care for myself with minimal assistance.I haven't had major heart issues or strokes in the last 6 months.I haven't fully recovered from a major surgery within the last 4 weeks.
- Group 1: Monotherapy with AGEN1777
- Group 2: AGEN1777 in combination with a PD-1 inhibitor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the research team currently seeking volunteers to participate in this exploration?
"Affirmative. Clinicaltrials.gov data suggests that recruitment for this research study is still ongoing, with the first posting on October 4th 2021 and most recent update on September 13th 2022. 75 individuals are being sought from 6 different sites to participate in the trial."
How many locations are engaged in this research endeavor?
"This study is ongoing in 6 different medical centres, including the University of Cincinnati Cancer Center, Mary Crowley Cancer Research and Providence Cancer Institute. Additionally there are other 3 sites offering this treatment."
Could you describe what safety risks might come with a prescription of PD-1 inhibitor?
"As this is a Phase 1 trial and there are limited results indicating the efficacy and safety of PD-1 inhibitors, it has been assigned a score of 1."
Share this study with friends
Copy Link
Messenger